Page 10 - க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவை Today - Breaking & Trending Today

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination
Posted On:
2020-12-29 01:49:21
(Time Zone: Arizona, USA)
Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed dose combination (FDC) of its novel, patent protected and globally researched Sodium Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) - Vildagliptin, in India. The fixed drug combination is indicated for the management of Type 2 diabetes. The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo V and Remozen V. ....

United States , Glenmark Remogliflozin , Remogliflozin Etabonate , Glenmark Remogliflozin Vildagiptin , Remogliflozin Vildagliptin , Alok Malik , Glenmark Pharmaceuticals Limited , Group Vice , Sodium Glucose Co , International Diabetes Federation , Time Zone , Pharmaceuticals Limited , Sodium Glucose Co Transporter Inhibitor , Dipeptidyl Peptidase , Group Vice President , Business Head , ஒன்றுபட்டது மாநிலங்களில் , அலோக் மாலிக் , க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவை , குழு துணை , சர்வதேச நீரிழிவு நோய் கூட்டமைப்பு , நேரம் ஸோந் , மருந்துகள் வரையறுக்கப்பட்டவை , குழு துணை ப்ரெஸிடெஂட் , வணிக தலை ,

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

Glenmark Logo
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India
ANI |
Updated: Dec 29, 2020 16:38 IST
Mumbai (Maharashtra) [India], December 29 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed dose combination (FDC) of its novel, patent protected and globally researched Sodium Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) - Vildagliptin, in India. The fixed drug combination is indicated for the management of Type 2 diabetes. The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo V an ....

Glenmark Remogliflozin , Remogliflozin Etabonate , Glenmark Remogliflozin Vildagiptin , Remogliflozin Vildagliptin , Alok Malik , Glenmark Pharmaceuticals Limited , Group Vice , Sodium Glucose Co , International Diabetes Federation , Sodium Glucose Co Transporter Inhibitor , Dipeptidyl Peptidase , Group Vice President , Business Head , Ther Clin Risk , அலோக் மாலிக் , க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவை , குழு துணை , சர்வதேச நீரிழிவு நோய் கூட்டமைப்பு , குழு துணை ப்ரெஸிடெஂட் , வணிக தலை , தெர் கிளினிக் ஆபத்து ,

Global Mental Disorder Treatment Market to Surpass US$ 75.7 Billion by 2027, Says Coherent Market Insights (CMI) – IT Business Net

Global Mental Disorder Treatment Market to Surpass US$ 75.7 Billion by 2027, Says Coherent Market Insights (CMI) – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , South Africa , South Korea , Asia Pacific , Eli Lilly , Janssen Pharmaceutica , Cipla Ltd , Sun Pharmaceutical Industries Ltd , Novartis International , Bristol Myers Squibb , Johnson Services Inc , Amneal Pharmaceuticals , World Health Organization , Drug Administration , Glenmark Pharmaceuticals , Group Therapists , Electronic Health Record , Sumitomo Dainippon Pharma Co Ltd , Mental Health Software Market , Business Development , Coherent Market Insights , Lupin Limited , United States Pharmacopeia , North America , Johnson Services ,

Global Mental Disorder Treatment Market to Surpass US$ 75.7 Billion by 2027, Says Coherent Market Insights (CMI) - Press Release

Related Market Intelligence Report:
Mental Health Software Market, by Deployment mode(On-premise and Subscription (Cloud-based)), by Mode of Access(Desktops/Laptops and Tablets/Smartphones), by Function(Telehealth, Payroll, Revenue Cycle Management (RCM),Ledger, Business Intelligence, Electronic Health Record (EHR) and Clinical Decision Support), by Application(Commercial, Hospitals and Clinics, Others(Psychiatrists, Social Workers, Psychologists, Counsellors, Nurse Practitioners, Group Therapists) and Residential) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
Depression Therapeutics Market, Drug Type (Antidepressants (Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), Serotonin Modulators, Tricyclic & Tetracyclic Antidepressants and Atypical Antidepressants), Antipsychotics and Others), by Indication (Major Depressi ....

United States , United Kingdom , South Africa , South Korea , Asia Pacific , Eli Lilly , Janssen Pharmaceutica , Cipla Ltd , Sun Pharmaceutical Industries Ltd , Novartis International , Bristol Myers Squibb , Johnson Services Inc , Amneal Pharmaceuticals , World Health Organization , Drug Administration , Glenmark Pharmaceuticals , Group Therapists , Electronic Health Record , Sumitomo Dainippon Pharma Co Ltd , Mental Health Software Market , Business Development , Business Wire , Coherent Market Insights , Lupin Limited , United States Pharmacopeia , North America ,

Volume Decline Muted Pharmaceutical Market Growth In November

Volume Decline Muted Pharmaceutical Market Growth In November
Volume Decline Muted Pharmaceutical Market Growth In November
The pharmaceutical market reported 128.3 billion total sales in November 2020 and decline in volume can be attributed to the lower sales of the acute therapy products
Pharmaceutical market reported Rs 128.3 billion total sales in November 2020
The sluggish growth of the Indian pharmaceutical market during November 2020 was largely led by a volume decline, while the growth in prices and new products remained healthy. The decline in volume can be attributed to the lower sales of the acute therapy products on account of a higher base in the corresponding month last year. According to a recent research report released by India Ratings and Research (Ind-Ra), the pharmaceutical market reported Rs 128.3 billion total sales in November 2020. On a monthly average total, for the past 12 months basis, the growth was 3.0 per cent for the same mo ....

Sun Pharmaceutical Industrials , Aristo Pharmaceuticals Private , Glenmark Pharmaceuticals , Research Ind , India Ratings , Glenmark Pharmaceuticals Limited , Aristo Pharmaceuticals Private Limited , Cipla Limited , Pharmaceutical Industrials Limited , சூரியன் மருந்து தொழில்கள் , அரிஸ்டோ மருந்துகள் ப்ரைவேட் , க்ளேண்மர்க் மருந்துகள் , ஆராய்ச்சி இந்த் , இந்தியா ரேடிஂக்ஸ் , க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவை , அரிஸ்டோ மருந்துகள் ப்ரைவேட் வரையறுக்கப்பட்டவை , சிப்லா வரையறுக்கப்பட்டவை , மருந்து தொழில்கள் வரையறுக்கப்பட்டவை ,